These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28742500)

  • 21. Metabolic effects of androgen deprivation therapy.
    Choi SM; Kam SC
    Korean J Urol; 2015 Jan; 56(1):12-8. PubMed ID: 25598932
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Emerging cardiometabolic complications of androgen deprivation therapy.
    Choong K; Basaria S
    Aging Male; 2010 Mar; 13(1):1-9. PubMed ID: 20148744
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A review of clinical effects associated with metabolic syndrome and exercise in prostate cancer patients.
    Kiwata JL; Dorff TB; Schroeder ET; Gross ME; Dieli-Conwright CM
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):323-332. PubMed ID: 27349496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Androgen deprivation therapy impact on quality of life and cardiovascular health, monitoring therapeutic replacement.
    Trost LW; Serefoglu E; Gokce A; Linder BJ; Sartor AO; Hellstrom WJ
    J Sex Med; 2013 Feb; 10 Suppl 1():84-101. PubMed ID: 23387914
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metabolic and cardiovascular effects of androgen deprivation therapy.
    Hakimian P; Blute M; Kashanian J; Chan S; Silver D; Shabsigh R
    BJU Int; 2008 Dec; 102(11):1509-14. PubMed ID: 18727614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Endocrine complications of androgen-deprivation therapy in men with prostate cancer.
    Harle LK; Maggio M; Shahani S; Braga-Basaria M; Basaria S
    Clin Adv Hematol Oncol; 2006 Sep; 4(9):687-96. PubMed ID: 17099626
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Androgen deprivation therapy in prostate cancer: focusing on sexual side effects.
    Corona G; Gacci M; Baldi E; Mancina R; Forti G; Maggi M
    J Sex Med; 2012 Mar; 9(3):887-902. PubMed ID: 22248394
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pathologic effects of testosterone deprivation.
    Sprenkle PC; Fisch H
    Curr Opin Urol; 2007 Nov; 17(6):424-30. PubMed ID: 17921778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.
    Braga-Basaria M; Dobs AS; Muller DC; Carducci MA; John M; Egan J; Basaria S
    J Clin Oncol; 2006 Aug; 24(24):3979-83. PubMed ID: 16921050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comprehensive Lifestyle Improvement Program for Prostate Cancer (CLIPP) is associated with improvement in weight and components of metabolic syndrome in men exposed to androgen deprivation therapy for prostate cancer.
    Algotar AM; Hsu CH; Chow HH; Dougherty ST; Babiker HM; Marrero DG; Abraham I; Kumar R; Ligibel JA; Courneya KS; Smith TE; Jones PA; Lopez JN; Niemiro G; Ramakumar S; Hoy RD; Mack C; Thomson CA
    Prostate Cancer Prostatic Dis; 2021 Sep; 24(3):903-909. PubMed ID: 33767355
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated?
    Grossmann M; Zajac JD
    Clin Endocrinol (Oxf); 2011 Mar; 74(3):289-93. PubMed ID: 21092052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The use of exercise interventions to overcome adverse effects of androgen deprivation therapy.
    Østergren PB; Kistorp C; Bennedbæk FN; Faber J; Sønksen J; Fode M
    Nat Rev Urol; 2016 Jun; 13(6):353-64. PubMed ID: 27112391
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Cardiovascular risks of androgen deprivation therapy for prostate cancer].
    Miller K
    Urologe A; 2016 May; 55(5):627-31. PubMed ID: 27003571
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Androgen deprivation therapy complications.
    Allan CA; Collins VR; Frydenberg M; McLachlan RI; Matthiesson KL
    Endocr Relat Cancer; 2014 Aug; 21(4):T119-29. PubMed ID: 24872511
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy.
    Basaria S; Muller DC; Carducci MA; Egan J; Dobs AS
    Cancer; 2006 Feb; 106(3):581-8. PubMed ID: 16388523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ADT risks and side effects in advanced prostate cancer: cardiovascular and acute renal injury.
    Crawford ED; Moul JW
    Oncology (Williston Park); 2015 Jan; 29(1):55-8, 65-6. PubMed ID: 25592210
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.
    Nobes JP; Langley SE; Klopper T; Russell-Jones D; Laing RW
    BJU Int; 2012 May; 109(10):1495-502. PubMed ID: 21933330
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Association between androgen-deprivation therapy and incidence of diabetes among males with prostate cancer.
    Lage MJ; Barber BL; Markus RA
    Urology; 2007 Dec; 70(6):1104-8. PubMed ID: 18158027
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse effects of androgen-deprivation therapy in prostate cancer and their management.
    Rhee H; Gunter JH; Heathcote P; Ho K; Stricker P; Corcoran NM; Nelson CC
    BJU Int; 2015 Apr; 115 Suppl 5():3-13. PubMed ID: 25327530
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Perspectives on the Cardiovascular and Metabolic Effects of Androgen Deprivation Therapy in Prostate Cancer.
    Sentana-Lledo D; Morgans AK
    Curr Oncol Rep; 2024 Mar; 26(3):299-306. PubMed ID: 38376624
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.